The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer

N/AUnknownNCT06208436

Tianjin Medical University Cancer Institute and Hospital250 enrolled

Overview

This study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with Stage I pancreatic cancer stratified by pathologic risk factors.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Pancreas Cancer Chemotherapy

Interventions

Adjuvant chemotherapyOTHER

Patients received adjuvant chemotherapy (5-FU-based or gemcitabine-based regimens) or underwent surgery alone

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients who underwent surgical resection and were pathologically diagnosed as PDAC between 2010 and 2021. \- Exclusion Criteria: Patients with pN1-N2, patients with pT3-T4, patients with distant metastasis, patients who received neoadjuvant therapy, patients with R1 resection, and patients who died due to perioperative mortality within 30 days. \-

Locations (1)

Jihui

Tianjin, Tianjin Municipality, China

RECRUITING

Outcomes

Primary Outcomes

Recurrence-free survival

The period between surgical resection to the date of recurrence.

Time frame: January 2010 to February 2023

Secondary Outcomes

Overall survival

The period between surgical resection to the date of death.

Time frame: January 2010 to February 2023

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.